UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
CANF holding history
Can-Fite BioPharma Ltd. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CANF overviewAll 13F holders of CANFFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −2,152−100.0% | Sold out | Holders |
| Q1 2026 | 2,152 | $6.67K | <0.1% | +1,105+105.5% | AddedConverted for a 1-for-20 split | Holders |
| Q4 2025 | 20,942 | $4.19K | <0.1% | +19,634+1,501.1% | Added | Holders |
| Q3 2025 | 1,308 | $810 | <0.1% | −4,207−76.3% | Reduced | Holders |
| Q2 2025 | 5,515 | $5.79K | <0.1% | +5,515 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −2,172−100.0% | Sold out | Holders |
| Q1 2024 | 2,172 | $4.82K | <0.1% | +2,172 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −714−100.0% | Sold out | Holders |
| Q1 2023 | 714 | $1.64K | <0.1% | −157−18.0% | ReducedConverted for a 1-for-10 split | Holders |
| Q4 2022 | 8,712 | $5.31K | <0.1% | −8,650−49.8% | Reduced | Holders |
| Q3 2022 | 17,362 | $13.0K | <0.1% | +9,841+130.8% | Added | Holders |
| Q2 2022 | 7,521 | $7.00K | <0.1% | +340+4.7% | Added | Holders |
| Q1 2022 | 7,181 | $9.00K | <0.1% | +7,181 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −7,709−100.0% | Sold out | Holders |
| Q2 2021 | 7,709 | $18.0K | <0.1% | +7,709 | New | Holders |